Antiretroviral News and Research

RSS

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

Progress in child survival worldwide is one of the greatest success stories of international development. Since 1990, child deaths have almost halved – falling from an estimated 90 deaths per 1000 live births to 46 deaths per 1000 live births in 2013...

13 May 2015

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

The University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, and GSK, a global, research-based pharmaceutical and healthcare company with a legacy of success in developing treatments for HIV, today announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS.

11 May 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

5 May 2015

AIDS patients at increased risk of developing intermediate-stage AMD

Patients with acquired immunodeficiency syndrome (AIDS) have a four-fold increase in their risk of developing intermediate-stage age-related macular degeneration (AMD) compared to people of the same age who are not infected with HIV, according to results from the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) presented today at the 2015 ARVO Annual Meeting in Denver, CO.

5 May 2015

Chickenpox virus can cause strokes in patients with compromised immune systems

Patients infected with human immunodeficiency virus (HIV) can, in rare cases, experience bleeding on the brain that causes a type of stroke called intracerebral hemorrhage.

5 May 2015

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV.

29 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients.

23 Apr 2015

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India.

23 Apr 2015

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Researchers have begun enrolling participants in a multicenter international clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events, such as heart attacks, strokes, and heart disease, in people with HIV infection. The trial is supported by the National Institutes of Health's National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases.

16 Apr 2015

Researchers use new gene editing tool to cut HIV DNA

The virus that causes AIDS is an efficient and crafty retrovirus. Once HIV inserts its DNA into the genome of its host cells, it has a long incubation period, and can remain dormant and hidden for years.

10 Apr 2015

Computer model provides policy prescription to optimize early HIV treatment

When a whole country's public health is at stake, making the wrong policy choices can cost lives and money. That's why researchers have worked to develop computer simulations of epidemics that can model individual behaviors and interactions to predict the spread of disease and the efficacy of interventions.

10 Apr 2015

US health care providers reluctant to prescribe HIV prevention plan

Many health care providers across the United States may be reluctant to prescribe an increasingly important prevention approach to some of their patients who are at substantial ongoing risk for HIV.

7 Apr 2015

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.

7 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

31 Mar 2015

Effective therapy enables immune system recovery in majority of children

Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after they begin treatment, according to a new study conducted by researchers at UCLA and other institutions in the U.S. and Brazil.

30 Mar 2015

Home-exercise plan for HIV patients

In addition to antiretroviral medications, people with HIV may soon begin receiving a home exercise plan from their doctors, according to a researcher at Case Western Reserve University's Frances Payne Bolton School of Nursing.

24 Mar 2015

Finding could improve global efforts to prevent HIV transmission, save lives

People who recently have been infected with HIV may not be as highly infectious as previously believed, a finding that could improve global efforts to prevent HIV transmission and save lives. In particular, the finding bolsters the strategy of treating patients with antiretroviral drugs before the onset of AIDS to prevent transmission.

18 Mar 2015

Antiretroviral News and Research

WHO Press Release: World Health Statistics reports on global health goals for 194 countries

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

Mylan releases generic version of Seasonale Tablets in the U.S.

AIDS patients at increased risk of developing intermediate-stage AMD

Chickenpox virus can cause strokes in patients with compromised immune systems

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

NIH-supported clinical trial to test statin use in patients with HIV-related cardiovascular disease

Researchers use new gene editing tool to cut HIV DNA

Computer model provides policy prescription to optimize early HIV treatment

US health care providers reluctant to prescribe HIV prevention plan

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Effective therapy enables immune system recovery in majority of children

Home-exercise plan for HIV patients

Finding could improve global efforts to prevent HIV transmission, save lives

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News